{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:40:46Z","timestamp":1793014846203,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40120-021-00273-0","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T15:02:45Z","timestamp":1629730965000},"page":"919-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"10","author":[{"given":"William L.","family":"Herring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian Gopal","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Fillit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Forrestal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pemberton-Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"273_CR1","unstructured":"Alzheimer's Society UK. Facts for the media 2021. https:\/\/www.alzheimers.org.uk\/about-us\/news-and-media\/facts-media."},{"key":"273_CR2","unstructured":"World Health Organization. Dementia: number of people affected to triple in next 30 years 2017. https:\/\/www.who.int\/news\/item\/07-12-2017-dementia-number-of-people-affected-to-triple-in-next-30-years. Accessed 27 July 2021."},{"key":"273_CR3","unstructured":"Alzheimer's Association. 2020 Alzheimer's disease facts and figures. https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full\/10.1002\/alz.12068. Accessed 27 July 2021."},{"key":"273_CR4","unstructured":"Centers for Disease Control and Prevention. Caregiving for a person with Alzheimer's disease or a related dementia. https:\/\/www.cdc.gov\/aging\/caregiving\/alzheimer.htm. Accessed 27 July 2021."},{"issue":"5054","key":"273_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184\u20135.","journal-title":"Science"},{"issue":"3","key":"273_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292\u2013323.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"273_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price JL, Morris JC. Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann Neurol. 1999;45(3):358\u201368.","journal-title":"Ann Neurol"},{"issue":"3","key":"273_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"273_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"key":"273_CR10","unstructured":"Centers for Disease Control and Prevention. CDC Wonder. Accessed [Jul 27, 2021]. https:\/\/wonder.cdc.gov\/"},{"key":"273_CR11","first-page":"1","volume":"2","author":"DS Knopman","year":"2016","unstructured":"Knopman DS, Gottesman RF, Sharrett AR, Wruck LM, Windham BG, Coker L, et al. Mild cognitive impairment and dementia prevalence: the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Alzheimers Dement. 2016;2:1\u201311.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"273_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/acps.12297","volume":"131","author":"R Lopez-Anton","year":"2015","unstructured":"Lopez-Anton R, Santabarbara J, De-la-Camara C, Gracia-Garcia P, Lobo E, Marcos G, et al. Mild cognitive impairment diagnosed with the new DSM-5 criteria: prevalence and associations with non-cognitive psychopathology. Acta Psychiatr Scand. 2015;131(1):29\u201339.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"273_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126\u201335.","journal-title":"Neurology"},{"issue":"13","key":"273_CR14","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286\u201394.","journal-title":"JAMA"},{"issue":"2","key":"273_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3233\/JAD-191212","volume":"75","author":"RL Robinson","year":"2020","unstructured":"Robinson RL, Rentz DM, Andrews JS, Zagar A, Kim Y, Bruemmer V, et al. Costs of early stage Alzheimer\u2019s disease in the United States: cross-sectional analysis of a prospective cohort study (GERAS-US)1. J Alzheimers Dis. 2020;75(2):437\u201350.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"273_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-122392","volume":"36","author":"A Wimo","year":"2013","unstructured":"Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, et al. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer\u2019s disease in three European countries\u2013study design and baseline findings. J Alzheimers Dis. 2013;36(2):385\u201399.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"273_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-190426","volume":"70","author":"YH El-Hayek","year":"2019","unstructured":"El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, et al. Tip of the Iceberg: assessing the global socioeconomic costs of Alzheimer\u2019s disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis. 2019;70(2):323\u201341.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"273_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jalz.2010.09.001","volume":"7","author":"A Gustavsson","year":"2011","unstructured":"Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B, et al. Predictors of costs of care in Alzheimer\u2019s disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011;7(3):318\u201327.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"273_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","volume":"15","author":"B Winblad","year":"2016","unstructured":"Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455\u2013532.","journal-title":"Lancet Neurol"},{"issue":"2","key":"273_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/14737167.2017.1313118","volume":"17","author":"A Deb","year":"2017","unstructured":"Deb A, Thornton JD, Sambamoorthi U, Innes K. Direct and indirect cost of managing Alzheimer\u2019s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res. 2017;17(2):189\u2013202.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"273_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14737167.2020.1822738","volume":"20","author":"A Gustavsson","year":"2020","unstructured":"Gustavsson A, Pemberton-Ross P, Gomez Montero M, Hashim M, Thompson R. Challenges in demonstrating the value of disease-modifying therapies for Alzheimer\u2019s disease. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):563\u201370.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"273_CR22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/13696998.2021.1927747","volume":"24","author":"C Makin","year":"2021","unstructured":"Makin C, Neumann P, Peschin S, Goldman D. Modelling the value of innovative treatments for Alzheimer\u2019s disease in the United States. J Med Econ. 2021;24(1):764\u20139.","journal-title":"J Med Econ"},{"issue":"3","key":"273_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-180766","volume":"67","author":"JL Cummings","year":"2019","unstructured":"Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer\u2019s disease: current and future pharmacotherapy options. J Alzheimers Dis. 2019;67(3):779\u201394.","journal-title":"J Alzheimers Dis"},{"issue":"16","key":"273_CR24","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2019.4782","volume":"322","author":"Z Arvanitakis","year":"2019","unstructured":"Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322(16):1589\u201399.","journal-title":"JAMA"},{"key":"273_CR25","unstructured":"Aduhelm (aducanumab-avwa). Prescribing information. Biogen, Inc; 2021 Accessed [July 27, 2021]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761178s000lbl.pdf"},{"issue":"7618","key":"273_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"key":"273_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/CEOR.S22265","volume":"3","author":"D Budd","year":"2011","unstructured":"Budd D, Burns LC, Guo Z, L\u2019Italien G, Lapuerta P. Impact of early intervention and disease modification in patients with predementia Alzheimer\u2019s disease: a Markov model simulation. Clinicoecon Outcomes Res. 2011;3:189\u201395.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"273_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40291-012-0010-7","volume":"16","author":"S Djalalov","year":"2012","unstructured":"Djalalov S, Yong J, Beca J, Black S, Saposnik G, Musa Z, et al. Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine. Mol Diagn Ther. 2012;16(6):389\u201399.","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"273_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1567205011310020011","volume":"10","author":"A Skoldunger","year":"2013","unstructured":"Skoldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer\u2019s disease\u2013a simulation study. Curr Alzheimer Res. 2013;10(2):207\u201316.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"273_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3233\/JAD-191055","volume":"75","author":"A Wimo","year":"2020","unstructured":"Wimo A, Handels R, Winblad B, Black CM, Johansson G, Salomonsson S, et al. Quantifying and describing the natural history and costs of Alzheimer\u2019s disease and effects of hypothetical interventions. J Alzheimers Dis. 2020;75(3):891\u2013902.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"273_CR31","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","volume":"65","author":"SE O'Bryant","year":"2008","unstructured":"O\u2019Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer\u2019s research consortium study. Arch Neurol. 2008;65(8):1091\u20135.","journal-title":"Arch Neurol"},{"issue":"6","key":"273_CR32","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force\u20133. Value Health. 2012;15(6):812\u201320.","journal-title":"Value Health"},{"issue":"3","key":"273_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"273_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"key":"273_CR35","unstructured":"Potashman M, Buessing M, Benea ML, Cummings J, Borson S, Pemberton-Ross P, et al., editors. Estimating progression rates across the spectrum of Alzheimer\u2019s disease for amyloid positive individuals using National Alzheimer\u2019s Coordinating Center data. Clinical Trials on Alzheimer's Disease Congress 2020; 2020. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7772113\/ shown as J Prev Alzheimers Dis. 202;7(suppl 1):55\u2013119. Poster 070. Accessed 27 July 2021."},{"issue":"8","key":"273_CR36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2174\/1567205015666180119092427","volume":"15","author":"M Davis","year":"2018","unstructured":"Davis M, Thomas OC, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer\u2019s disease progression rates from normal cognition through mild cognitive impairment and stages of dementia. Curr Alzheimer Res. 2018;15(8):777\u201388.","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"273_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/00019053-200017040-00005","volume":"17","author":"AB Hauber","year":"2000","unstructured":"Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA. Potential savings in the cost of caring for Alzheimer\u2019s disease. Treatment with rivastigmine. Pharmacoeconomics. 2000;17(4):351\u201360.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"273_CR38","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1212\/WNL.52.6.1138","volume":"52","author":"PJ Neumann","year":"1999","unstructured":"Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer\u2019s disease. Neurology. 1999;52(6):1138\u201345.","journal-title":"Neurology"},{"issue":"9","key":"273_CR39","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2174\/156720512803569046","volume":"9","author":"DE Spackman","year":"2012","unstructured":"Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS. Curr Alzheimer Res. 2012;9(9):1050\u20138.","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"273_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00005650-199901000-00005","volume":"37","author":"PJ Neumann","year":"1999","unstructured":"Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, et al. Health utilities in Alzheimer\u2019s disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37(1):27\u201332.","journal-title":"Med Care"},{"issue":"6","key":"273_CR41","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/archneurol.2009.80","volume":"66","author":"RS Wilson","year":"2009","unstructured":"Wilson RS, Aggarwal NT, Barnes LL, Bienias JL, Mendes de Leon CF, Evans DA. Biracial population study of mortality in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2009;66(6):767\u201372.","journal-title":"Arch Neurol"},{"issue":"7","key":"273_CR42","first-page":"1","volume":"68","author":"E Arias","year":"2019","unstructured":"Arias E, Xu J. United States life tables, 2017. Natl Vital Stat Rep. 2019;68(7):1\u201366.","journal-title":"Natl Vital Stat Rep"},{"issue":"1","key":"273_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000265553","volume":"29","author":"K Andersen","year":"2010","unstructured":"Andersen K, Lolk A, Martinussen T, Kragh-Sorensen P. Very mild to severe dementia and mortality: a 14-year follow-up\u2014the Odense study. Dement Geriatr Cogn Disord. 2010;29(1):61\u20137.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"273_CR44","unstructured":"von Rosenstiel P, Haeberlein S, Castrillo-Viguera C, Chen T, O\u2019Gorman J, Rajagovindan R, et al., editors. Aducanumab 48-month analyses from PRIME, a phase 1b study in patients with early Alzheimer\u2019s disease. 11th Clinical Trials on Alzheimer\u2019s Disease Congress 2018; 2018; Barcelona, Spain."},{"issue":"1","key":"273_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13195-020-00723-1","volume":"12","author":"F Landeiro","year":"2020","unstructured":"Landeiro F, Mughal S, Walsh K, Nye E, Morton J, Williams H, et al. Health-related quality of life in people with predementia Alzheimer\u2019s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12(1):154.","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"273_CR46","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.jagp.2015.07.002","volume":"23","author":"K Hongisto","year":"2015","unstructured":"Hongisto K, Vaatainen S, Martikainen J, Hallikainen I, Valimaki T, Hartikainen S, et al. Self-rated and caregiver-rated quality of life in Alzheimer disease with a focus on evolving patient ability to respond to questionnaires: 5-year prospective ALSOVA Cohort Study. Am J Geriatr Psychiatry. 2015;23(12):1280\u20139.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"273_CR47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/156720510791162430","volume":"7","author":"J Mesterton","year":"2010","unstructured":"Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jonsson L. Cross sectional observational study on the societal costs of Alzheimer\u2019s disease. Curr Alzheimer Res. 2010;7(4):358\u201367.","journal-title":"Curr Alzheimer Res"},{"key":"273_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-94-007-7596-1_3","volume-title":"Self-reported population health: an international perspective based on EQ-5D","author":"B Janssen","year":"2014","unstructured":"Janssen B, Szende A. Population norms for the EQ-5D. In: Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer; 2014. p. 19\u201330."},{"key":"273_CR49","unstructured":"ICER. A guide to ICER's methods for health technology assessment. 2018. http:\/\/icer-review.org\/wp-content\/uploads\/2018\/08\/ICER-HTA-Guide_082018.pdf. Accessed 27 July 2021."},{"issue":"10","key":"273_CR50","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"issue":"10","key":"273_CR51","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jalz.2019.05.004","volume":"15","author":"C Green","year":"2019","unstructured":"Green C, Handels R, Gustavsson A, Wimo A, Winblad B, Skoldunger A, et al. Assessing cost-effectiveness of early intervention in Alzheimer\u2019s disease: An open-source modeling framework. Alzheimers Dement. 2019;15(10):1309\u201321.","journal-title":"Alzheimers Dement"},{"key":"273_CR52","unstructured":"IPECAD Modelling Group. The IPECAD Open-Source Model Version 1.1. 2021 2021 [Available from: https:\/\/ipecadgroup.wordpress.com\/open-source-model\/. Accessed 1 Mar 2021."},{"issue":"7","key":"273_CR53","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15(7):888\u201398.","journal-title":"Alzheimers Dement"},{"key":"273_CR54","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.trci.2018.01.001","volume":"4","author":"AR Kansal","year":"2018","unstructured":"Kansal AR, Tafazzoli A, Ishak KJ, Krotneva S. Alzheimer\u2019s disease archimedes condition-event simulator: development and validation. Alzheimers Dement (NY). 2018;4:76\u201388.","journal-title":"Alzheimers Dement (NY)"},{"issue":"6","key":"273_CR55","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/acn3.782","volume":"6","author":"L Iaccarino","year":"2019","unstructured":"Iaccarino L, Sala A, Perani D. Alzheimer\u2019s disease neuroimaging I. Predicting long-term clinical stability in amyloid-positive subjects by FDG-PET. Ann Clin Transl Neurol. 2019;6(6):1113\u201320.","journal-title":"Ann Clin Transl Neurol"},{"issue":"Pt 5","key":"273_CR56","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/brain\/awv029","volume":"138","author":"SJ Vos","year":"2015","unstructured":"Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W, et al. Prevalence and prognosis of Alzheimer\u2019s disease at the mild cognitive impairment stage. Brain. 2015;138(Pt 5):1327\u201338.","journal-title":"Brain"},{"key":"273_CR57","unstructured":"US Food and Drug Administration. Expedited programs for serious conditions\u2013drugs and biologics. 2014.  https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-serious-conditions-drugs-and-biologics. Accessed 27 July 2021."},{"key":"273_CR58","unstructured":"Alzheimer's Association. Changing the trajectory of Alzheimer\u2019s disease: How a treatment by 2025 saves lives and dollars 2015. https:\/\/www.alz.org\/media\/documents\/changing-the-trajectory-r.pdf. Accessed 27 July 2021."},{"issue":"10","key":"273_CR59","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2012;366(10):893\u2013903.","journal-title":"N Engl J Med"},{"key":"273_CR60","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.dadm.2017.05.006","volume":"8","author":"KD Harrington","year":"2017","unstructured":"Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Martins RN, et al. Amyloid beta-associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimers Dement (Amst). 2017;8:156\u201364.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"273_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jalz.2009.05.665","volume":"6","author":"K Ito","year":"2010","unstructured":"Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T, et al. Disease progression meta-analysis model in Alzheimer\u2019s disease. Alzheimers Dement. 2010;6(1):39\u201353.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"273_CR62","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/alzrt210","volume":"5","author":"C Wattmo","year":"2013","unstructured":"Wattmo C, Wallin AK, Minthon L. Progression of mild Alzheimer\u2019s disease: knowledge and prediction models required for future treatment strategies. Alzheimers Res Ther. 2013;5(5):44.","journal-title":"Alzheimers Res Ther"},{"issue":"7122","key":"273_CR63","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1136\/bmj.315.7122.1577","volume":"315","author":"J Caro","year":"1997","unstructured":"Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettitt D, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ. 1997;315(7122):1577\u201382.","journal-title":"BMJ"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00273-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-021-00273-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00273-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T17:25:47Z","timestamp":1675617947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-021-00273-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["273"],"URL":"https:\/\/doi.org\/10.1007\/s40120-021-00273-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}